Arch Therapeutics, Inc. ('Arch' or the 'Company') announced that it has launched a multi-site clinical study (the 'Study') to accelerate payor adoption and differentiate the key benefits of AC5® Advanced Wound System ('AC5') in treating challenging wounds. The Study is expected to enroll and treat up to 60 patients at six sites with a primary end point of wound closure. The launch of the Study completes the near-term commitments listed in the Company's recently announced reimbursement initiative to accelerate sales opportunities for AC5 in doctor's offices and wound care clinics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | 0.00% | +9.47% | -85.64% |
1st Jan change | Capi. | |
---|---|---|
-85.64% | 4.62M | |
+8.29% | 124B | |
-5.61% | 11.02B | |
+4.83% | 8.88B | |
+39.60% | 5.45B | |
-22.04% | 4.74B | |
+8.39% | 3.44B | |
-6.28% | 2.84B | |
-10.23% | 2.15B | |
-5.99% | 2.11B |
- Stock Market
- Equities
- ARTH Stock
- News Arch Therapeutics, Inc.
- Arch Therapeutics, Inc. Launches Multi-Site Clinical Study for AC5® Advanced Wound System